Skip to main content

Nasdaq FB FaceBook

89Bio To Present ENTRIGUE Trial Data On Aug. 26

4 years 2 months ago
(RTTNews) - 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development of the treatment of liver and cardio-metabolic diseases, will present the topline results of Phase-2 ENTRIGUE trial of Pegozafermin for the treatment of severe Hypertriglyceride
Checked
11 minutes 5 seconds ago
This feed is responsible for generating the rss feed related to the topic META
Subscribe to Nasdaq FB FaceBook feed